Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Syndax Pharmaceuticals (SNDX) Non Operating Income (2016 - 2020)

Syndax Pharmaceuticals (SNDX) has disclosed Non Operating Income for 6 consecutive years, with -$563000.0 as the latest value for Q4 2020.

  • For Q4 2020, Non Operating Income fell 374.63% year-over-year to -$563000.0; the TTM value through Dec 2020 reached -$1.7 million, down 216.29%, while the annual FY2025 figure was -$12.3 million, 158.99% down from the prior year.
  • Non Operating Income hit -$563000.0 in Q4 2020 for Syndax Pharmaceuticals, up from -$584000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $563000.0 in Q2 2018 and bottomed at -$1.6 million in Q1 2016.
  • Average Non Operating Income over 5 years is $105900.0, with a median of $298000.0 recorded in 2016.
  • Year-over-year, Non Operating Income skyrocketed 177.34% in 2018 and then crashed 374.63% in 2020.
  • Syndax Pharmaceuticals' Non Operating Income stood at $326000.0 in 2016, then increased by 18.1% to $385000.0 in 2017, then increased by 28.83% to $496000.0 in 2018, then tumbled by 58.67% to $205000.0 in 2019, then plummeted by 374.63% to -$563000.0 in 2020.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$563000.0, -$584000.0, and -$452000.0 for Q4 2020, Q3 2020, and Q2 2020 respectively.